Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de Fedratinib em indivíduos japoneses com DIPSS (Dynamic International Prognostic Scoring System) - Mielofibrose primária (PMF) de risco intermediário ou alto, Mielofibrose Vera pós-policitemia (MF pós-PV) ou Mielofibrose pós-trombocitemia essencial (Pós-ET MF)

8 de novembro de 2026 atualizado por: Bristol-Myers Squibb

Um estudo aberto de Fase 1/2, multicêntrico, de braço único para avaliar a eficácia e a segurança do Fedratinibe em indivíduos japoneses com DIPSS (Sistema de Pontuação de Prognóstico Dinâmico Internacional) - Mielofibrose primária (PMF) de risco intermediário ou alto, pós- policitemia Vera Mielofibrose (pós-PV MF), ou pós-trombocitemia essencial Mielofibrose (pós-ET MF)

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.

This is a Phase 1/2 multicenter, single arm, open-label study in Japanese subjects with DIPSS intermediate or high-risk PMF, post-PV or post-ET MF. The study consists of 2 parts: Phase 1 part to determine safety and tolerability and a RP2D. The Phase 1 portion of the study will explore one or more drug doses for fedratinib (300 mg and 400 mg) using a mTPI-2 design. Following completion of dose escalation and determination of MTD and/or a RP2D, the study will progress into the Phase 2 part to further evaluate the efficacy and safety.

The study will consist of 3 periods: a Screening Period, a Treatment Period including a 30-day follow-up after last dose visit and a survival follow-up period.

Visão geral do estudo

Status

Concluído

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

31

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Aomori, Japão, 030-8553
        • Local Institution - 002
      • Bunkyō City, Japão, 113-8677
        • Local Institution - 004
      • Fukuoka, Japão, 812-8582
        • Local Institution - 015
      • Hitachi, Ibaraki, Japão, 317-0077
        • Local Institution - 018
      • Isehara City, Kanagawa, Japão, 259-1193
        • Local Institution - 005
      • Kamogawa, Japão, 296-8602
        • Local Institution - 010
      • Kitakyushu, Japão, 806-8501
        • Local Institution - 017
      • Kumamoto, Japão, 8628655
        • Local Institution - 020
      • Maebashi, Japão, 371-8511
        • Local Institution - 013
      • Miyazaki, Japão, 889-1692
        • Local Institution - 012
      • Nagasaki, Japão, 8528511
        • Local Institution - 009
      • Osaka, Japão, 545-8586
        • Local Institution - 016
      • Sapporo, Japão, 003-0006
        • Local Institution - 014
      • Shinagawa-ku, Tokyo, Japão, 141-8625
        • Local Institution - 007
      • Shinjuku, Japão, 162-8666
        • Local Institution - 008
      • Shinjyuku-ku, Japão, 160-0023
        • Local Institution - 003
      • Takamatsu, Japão, 760-0017
        • Local Institution - 019
      • Ōsaka-sayama, Japão, 589-8511
        • Local Institution - 011
    • Nagano
      • Suwa, Nagano, Japão, 392-8510
        • Local Institution - 021
    • Tokyo
      • Bunkyo-ku, Tokyo, Japão, 113-8431
        • Local Institution - 001
    • Yamanashi
      • Chūō, Yamanashi, Japão, 409-3898
        • Local Institution - 006

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

20 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Subject is ≥ 20 years of age at the time of signing the informed consent form (ICF)

  2. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2

  3. Subject has diagnosis of Primary myelofibrosis (PMF) according to the 2016 World Health Organization (WHO) criteria, or diagnosis of post-ET or post- Polycythemia vera (PV) Myelofibrosis (MF) according to the IWG-MRT 2007 criteria, confirmed by the most recent local pathology report

  4. Subject has a Dynamic International Prognostic Scoring System (DIPSS) Risk score of Intermediate-1 with symptom(s), Intermediate-2 or High

  5. Subject has a measurable splenomegaly during the screening period as demonstrated by spleen volume of ≥ 450 cm3 by magnetic resonance imaging (MRI) or computed tomography (CT) scan or by palpable spleen measuring ≥ 5 cm below the left costal margin.

  6. Subject must meet at least one of the following criteria of (a or b).

    Note: reason to discontinue ruxolitinib treatment (lack of efficacy and/or intolerability, etc) and physician decision as to the study participation as being appropriate should be recorded in the case report form:

    1. Previously received ruxolitinib treatment for PMF or post-PV MF or post-ET MF for at least 14 days (exposure of < 14 days is allowed for subjects who discontinued ruxolitinib due to intolerability or allergy).
    2. Never received ruxolitinib treatment and is expected to derive clinical benefit from this study participation based on the clinical judgement of the Investigator Only those subjects who previously received ruxolitinib treatment are eligible for the Phase 1 part of the study to avoid overestimating tolerability of fedratinib.
  7. Subject must have treatment-related toxicities from prior therapy resolved to Grade 1 or pretreatment baseline before start of last therapy prior to starting the fedratinib treatment.

  8. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

  9. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

  10. A female of childbearing potential (FCBP) must:

    1. Have 2 negative pregnancy tests as verified by the Investigator during screening prior to starting fedratinib treatment. She must agree to ongoing pregnancy testing during the course of the study, and after end of fedratinib treatment. This applies even if the subject practices true abstinence* from heterosexual contact.
    2. Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use and be able to comply with highly effective contraception** without interruption, -14 days prior to starting investigational product, during the fedratinib treatment (including dose interruptions), and for 30 days after discontinuation of fedratinib treatment.
    3. If breastfeeding, agree to stop breastfeeding prior to the participation in the study and not to resume breastfeeding for at least 30 days after treatment discontinuation of the fedratinib treatment.

    Note: A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy or amenorrhea due to other medical reasons does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).

  11. A male subject must:

Practice true abstinence (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 30 days following fedratinib discontinuation, or longer if required by local regulations, even if he has undergone a successful vasectomy.

True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] and withdrawal are not acceptable methods of contraception).

Agreement to use highly effective methods of contraception that alone or in combination resulting in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include combined (estrogen and progestogen containing) hormonal contraception (oral), progestogen-only hormonal contraception associated with inhibition of ovulation (oral), placement of an intrauterine device, placement of an intrauterine hormone-releasing system, bilateral tubal occlusion, and vasectomized partner.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Any of the following laboratory abnormalities:

    1. Platelets < 50 x 109/L (without platelet transfusion)
    2. Absolute neutrophil count (ANC) < 1.0 x 109/L
    3. White blood count (WBC) > 100 x 109/L
    4. Myeloblasts ≥ 5 % in peripheral blood
    5. Estimated creatinine clearance < 30 mL/min (as estimated by Cockcroft-Gault formula)
    6. Serum amylase or lipase > 1.5 x upper limit of normal
    7. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x upper limit of normal (ULN)
    8. Total bilirubin > 1.5 x ULN, subject's total bilirubin between 1.5 - 3.0 x ULN are eligible if the direct bilirubin fraction is < 25% of the total bilirubin.
  2. Subject is pregnant or breastfeeding female.

  3. Subject with previous splenectomy

  4. Subject with previous or planned hematopoietic Stem-cell transplantation (SCT)

  5. Subject with prior history of Encephalopathy, including Wernicke encephalopathy (WE)

  6. Subject with signs or symptoms of encephalopathy, including WE (eg, severe ataxia, ocular paralysis or cerebellar signs) without documented exclusion of WE by thiamine level and brain MRI

  7. Subject with thiamine deficiency, defined as thiamine levels in whole blood below normal range according to institutional standard and not demonstrated to be corrected prior to starting the fedratinib treatment

  8. Subject with concomitant treatment with or use of pharmaceutical, herbal agents or food known to be strong or moderate inducers of Cytochrome P450 (CYP) 3A4, and dual CYP2C19 and CYP3A4 inhibitors

  9. Subject on any chemotherapy, immunomodulatory drug therapy (eg, thalidomide, interferon-alpha), anagrelide, immunosuppressive therapy, systemic corticosteroids > 10 mg/day prednisone or equivalent. Subjects who have had prior exposure to hydroxyurea (eg, Hydrea) in the past may be enrolled into the study as long as it has not been administered within 14 days prior to starting the fedratinib treatment.

  10. Subject on treatment with myeloid growth factor (eg, granulocyte-colony stimulating factor [G-CSF]) within 14 days prior to starting the fedratinib treatment

  11. Subject with previous exposure to JAK inhibitor(s) other than ruxolitinib treatment

  12. Subject has received ruxolitinib within 14 days prior to starting the fedratinib treatment

  13. Subject on treatment with aspirin with doses > 150 mg daily

  14. Subject with major surgery within 28 days prior to starting the fedratinib treatment

  15. Subject with diagnosis of chronic liver disease (eg, chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemochromatosis, non-alcoholic steatohepatitis)

  16. Subject with prior malignancy other than the disease under study unless the subject has not required treatment for the malignancy for at least 3 years prior to the start of fedratinib treatment. However, subject with the following history/concurrent conditions provided successfully treated may enroll: non-invasive skin cancer, in situ cervical cancer, carcinoma in situ of the breast, incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system), or is free of disease and on hormonal treatment only

  17. Subject with uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4)

  18. Seropositive for and with evidence of active viral infection with hepatitis B virus (HBV)

    1. Subject who are hepatitis B surface antigen (HBsAg) negative but HB core anti-body (HBcAb) positive or HBsAb positive are eligible in case HBV viral deoxyribonucleoside (DNA) negative
    2. Subject who had HBsAg positive but show non-detectable viral DNA for at least 6 months prior to starting the fedratinib treatment where appropriate anti-viral treatment should have been given/considered to prevent HBV reactivation based on the standard practice are eligible
    3. Subject who are seropositive because of hepatitis B virus vaccine are eligible
  19. Seropositive for and with active viral infection with hepatitis C virus (HCV)

    • Subject who had hepatitis C but show no detectable HCV viral ribonucleotide (RNA) for at least 6 months prior to starting the fedratinib treatment are eligible.

  20. Evidence of human immunodeficiency virus (HIV) infection.

  21. Subject with serious active infection

    • Additionally, subject with history of active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks prior to screening, unless the subject has adequately recovered from coronavirus disease (COVID) symptoms and related complications as per investigator's discretion, and following a discussion with the Medical Monitor.

  22. Subject with presence of any significant gastric or other disorder that would inhibit absorption of oral medication

  23. Subject is unable to swallow capsule

  24. Subject with any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study

  25. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if the subject were to participate in the study

  26. Subject has any condition that confounds the ability to interpret data from the study

  27. Subject with participation in any study of an investigational agent (drug, biologic, device) within 30 days prior to starting the fedratinib treatment

  28. Subject with a life expectancy of less than 6 months from the planned first dose of fedratinib.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Fedratinib Administration

The fedratinib dose is 300 or 400 mg/day PO (3 or 4 x 100 mg capsules) to be self-administered orally once daily continuously on an outpatient basis, preferably together with food during an evening meal, the same time each day.

Specified dose on specified days

Outros nomes:
  • BMS-847943

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Maximum Tolerated Dose (MTD)
Prazo: Up to Cycle 1 (each cycle is 28 days)

is the highest dose that causes DLTs in not more than 33% of the subjects treated with fedratinib in the first cycle with at least 3 evaluable subjects treated at this dose.

Up to Cycle 1 (each cycle is 28 days)
Recommended Phase 2 dose (RP2D)
Prazo: Up to Cycle 1 (each cycle is 28 days)

is a recommended Phase 2 dose that is determined as safe and tolerable by the Safety Review Committee based on the data from the first cycle with at least 3 evaluable subjects treated at each dose of the Phase 1 part.

Up to Cycle 1 (each cycle is 28 days)
Response Rate (RR)
Prazo: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects who have ≥ 35% SVR at end of Cycle 6 from baseline

Up to Cycle 6 (each cycle is 28 days)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Adverse Events (AEs)
Prazo: From ICF signature up until 30 days after last dose of IP

An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

From ICF signature up until 30 days after last dose of IP
Pharmacokinetics - Cmax
Prazo: Up to Cycle 1 (each cycle is 28 days)

Peak (maximum) plasma concentration of the drug

Up to Cycle 1 (each cycle is 28 days)
Pharmacokinetics - AUC
Prazo: Up to Cycle 1 (each cycle is 28 days)

Area under the plasma concentration curve

Up to Cycle 1 (each cycle is 28 days)
Pharmacokinetics - Tmax
Prazo: Up to Cycle 1 (each cycle is 28 days)

Time to maximum plasma concentration

Up to Cycle 1 (each cycle is 28 days)
Symptom response rate (SRR)
Prazo: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects with ≥ 50% reduction in total symptom scores measured by MFSAF version 2.0 (Appendix C) at end of Cycle 6

Up to Cycle 6 (each cycle is 28 days)
Spleen volume response rate 25 (RR25)
Prazo: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects who have ≥ 25% reduction in spleen volume at the end of Cycle 6

Up to Cycle 6 (each cycle is 28 days)
Spleen Response Rate by Palpation (RRP)
Prazo: Up to Cycle 6 (each cycle is 28 days)

Proportion of subjects who have ≥ 50% reduction in spleen size by palpation at end of Cycle 6

Up to Cycle 6 (each cycle is 28 days)
Duration of spleen volume response (DR)
Prazo: Up to 4 years

Duration of ≥ 35% SVR by MRI/CT

Up to 4 years
Duration of spleen response by palpation (DRP)
Prazo: Up to 4 years

Time from the first documented palpable spleen response, according to the IWGMRT 2013 to the time of the first documented loss of response according to the IWG-MRT 2013.

Up to 4 years
Duration of symptoms response (DSR)
Prazo: Up to 4 years

Duration of ≥ 50% reduction in total symptom scores measured by MFSAF version 2.0

Up to 4 years
Spleen and Disease Progression Free Survival (SDPFS)
Prazo: Up to 4 years

Time from the start of fedratinib treatment to death due to any reason or disease progression (modified IWGMRT 2013 including ≥ 25% increase in spleen volume by MRI/CT)

Up to 4 years
Gastrointestinal adverse events
Prazo: From ICF signature to the 30-day follow-up after last dose of IP

Incidence of subjects with Grade 3 or higher Gastrointestinal events (nausea, diarrhea, or vomiting) according to CTCAE v5.0

From ICF signature to the 30-day follow-up after last dose of IP
Wernicke encephalopathy (WE) events
Prazo: From ICF signature to the 30-day follow-up after last dose of IP

Occurrence of confirmed Wernicke encephalopathy events

From ICF signature to the 30-day follow-up after last dose of IP
Overall Survival (OS)
Prazo: Up to 4 years

Time from the start of fedratinib treatment to death due to any reason

Up to 4 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Bristol-Myers Squibb, Bristol-Myers Squibb
  • Diretor de estudo: Bristol Myers Squibb, Bristol-Myers Squibb

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

12 de outubro de 2020

Conclusão Primária (Real)

5 de outubro de 2023

Conclusão do estudo (Real)

16 de outubro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

16 de junho de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

23 de junho de 2020

Primeira postagem (Real)

25 de junho de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

12 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

8 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • FEDR-MF-003

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Prazo de Compartilhamento de IPD

See Plan Description

Critérios de acesso de compartilhamento IPD

See Plan Description

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever